FCGRT and chronic inflammatory demyelinating polyradiculoneuropathy: Beyond this, novel treatment classes for CIDP, such as B‐cell inhibitors, complement inhibitors, and neonatal fragment crystallizable receptor (FcRn) blockers, are currently being investigated in clinical trials [12], with a FcRn blocker recently receiving US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval for the treatment of CIDP in 2024 and 2025, respectively [13, 14].